EPRX
What one share of Eupraxia Pharmaceuticals holds
Pharmaceutical Preparations
On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE including the demonstration of near-complete improvement on biopsy in the highest dosed group.
Eupraxia Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.00 |
|---|---|
| Profit | −$1.03 |
| Cash and investments | $1.55 |
| Book value | $1.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.96 | — | −$0.75 | — | $0.36 |
| 2023 | $0.00 | −$1.17 | — | −$0.86 | — | $0.08 |
| 2024 | $0.00 | −$0.76 | — | −$0.88 | — | $0.94 |
| 2025 | $0.00 | −$1.03 | — | −$0.71 | — | $1.58 |